A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2016
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Uveitis
- Focus Registrational; Therapeutic Use
- Sponsors pSivida
- 22 Dec 2016 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
- 22 Dec 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Aug 2017.
- 22 Dec 2016 Status changed from recruiting to active, no longer recruiting.